Logo

SVRA

Savara Inc.

SVRA

Savara Inc. • NASDAQ
$6.28 ▲ 17.07% (+0.92)
Market Cap $1.28 B
52w High $6.37
52w Low $1.89
Dividend Yield 0%
P/E -11.84
Volume 6.56M
Outstanding Shares 203.47M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $30.255M ▼ $-29.561M ▲ 0% $-0.14 $-29.486M ▲
Q2-2025 $0 $31.055M ▲ $-30.401M ▼ 0% $-0.14 ▼ $-31.407M ▼
Q1-2025 $0 $27.53M ▼ $-26.639M ▲ 0% $-0.12 ▲ $-27.621M ▲
Q4-2024 $0 $31.104M ▲ $-29.044M ▼ 0% $-0.14 ▼ $-28.974M ▼
Q3-2024 $0 $6.046M $-24.248M 0% $-0.11 $-26.324M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $124.386M ▼ $140.924M ▼ $46.538M ▲ $94.386M ▼
Q2-2025 $146.443M ▼ $163.765M ▼ $43.281M ▲ $120.484M ▼
Q1-2025 $172.5M ▼ $189.316M ▼ $41.466M ▲ $147.85M ▼
Q4-2024 $196.327M ▼ $212.879M ▼ $41.43M ▲ $171.449M ▼
Q3-2024 $219.44M $238.817M $39.468M $199.349M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-29.561M ▲ $-22.53M ▲ $21.468M ▼ $-23K ▲ $-1.159M ▲ $-22.532M ▲
Q2-2025 $-30.401M ▼ $-26.261M ▲ $24.327M ▼ $-49K ▼ $-2.12M ▼ $-26.276M ▲
Q1-2025 $-26.639M ▲ $-27.189M ▼ $29.329M ▲ $2.318M ▲ $4.428M ▲ $-27.192M ▼
Q4-2024 $-29.044M ▼ $-23.281M ▼ $17.895M ▲ $-843K ▼ $-6.299M ▼ $-23.272M ▼
Q3-2024 $-24.248M $-22.668M $-98.167M $118.316M $-2.437M $-22.671M

Five-Year Company Overview

Income Statement

Income Statement Savara looks like a classic clinical‑stage biotech: essentially no product revenue yet and steady net losses each year. The good news is that losses have not exploded; they have been relatively contained and fairly predictable, which suggests disciplined spending. Most of the income statement reflects R&D and development costs for the lead asset rather than a broad commercial operation. Profitability will depend entirely on whether the lead drug is approved and how quickly it ramps once on the market.

Balance Sheet

Balance Sheet The balance sheet is small but has been gradually strengthening. Assets and shareholders’ equity have both increased over time, showing the company has been able to raise capital and build a financial cushion rather than running on fumes. Debt is present but not dominant, implying the capital structure is more equity‑funded than debt‑heavy. Cash is meaningful but not huge, so there is some runway, yet the company is not in a position to fund long-term operations without eventual additional financing if approval and revenue are delayed.

Cash Flow

Cash Flow Cash flow is negative, driven by operating losses tied to clinical development and pre‑commercial activities. The cash burn has been steady rather than sharply accelerating, and there is essentially no spending on big physical assets, which keeps capital needs somewhat simpler. Still, this is a cash‑consuming business today, not a cash‑generating one. Unless molgramostim gets approved and begins to generate sales, the company will likely remain dependent on external funding to support operations.

Competitive Edge

Competitive Edge Savara’s competitive position is unusually strong for such a small company because it is targeting a rare disease with no approved drug treatments. If its inhaled molgramostim is approved, it could become the first and only medicine for this condition, displacing a burdensome surgical‑type procedure. Orphan and other expedited regulatory designations add layers of protection and support, and the exclusive partnership around the specialized nebulizer deepens the moat. The flip side is that this strength rests almost entirely on one product in one niche market, so any setback in that program has an outsized impact.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Savara’s story. The company has advanced an inhaled biologic with a targeted delivery system through late‑stage trials, with solid evidence of clinical benefit. The diagnostic test to find patients and confirm disease adds another innovative angle and helps define the market. However, Savara has largely narrowed its pipeline to this single program, which is both a strength (focus and resource concentration) and a vulnerability (limited diversification). The recent regulatory filing setback appears to be about manufacturing and quality documentation rather than drug performance, but it still introduces timing and execution risk while the company works to resubmit.

Summary

Overall, Savara is a focused, late‑stage, pre‑revenue biotech built almost entirely around one promising inhaled therapy for a rare lung disease. Financially, it runs predictable losses and burns cash, but it has gradually strengthened its capital base and does not appear over‑levered. Strategically, it holds an attractive potential first‑mover position, supported by regulatory incentives and a device‑drug combination that is hard to copy. The main uncertainties relate to regulatory resubmission, manufacturing readiness, and how effectively the company can commercialize and eventually diversify beyond a single product once, and if, approval is secured.

NEWS

November 20, 2025 · 4:05 PM UTC

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Read more

November 12, 2025 · 4:05 PM UTC

Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

Read more

November 7, 2025 · 9:43 PM UTC

SVRA DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Savara Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action - SVRA

Read more

November 7, 2025 · 4:00 PM UTC

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Savara Inc.(SVRA) Shareholders

Read more

November 7, 2025 · 10:13 AM UTC

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Read more